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Case report
Cushing syndrome (CS) is rare in children. The clinical presentation of CS varies 
according to extent and duration of glucocorticoid excess, and urolithiasis is a 
common complication. We report the first case of a patient with CS associated 
with acute kidney injury (AKI) due to urolithiasis. A 6-year-old boy presented 
to the Emergency Department with seizure. On physical examination, he had 
clinical features of CS and high blood pressure. Brain computed tomography (CT) 
suggested posterior reversible encephalopathy syndrome due to hypertension. 
On evaluation of hypertension, laboratory tests suggested adrenocortical tumor, 
but abdominal CT suggested pheochromocytoma. During further evaluation, 
his condition deteriorated with AKI due to bilateral ureteral stones, for which the 
patient underwent continuous renal replacement therapy in the intensive care 
unit. After controlling hypercortisolism with etomidate and performing ureteral 
stent indwelling, an adrenal mass was resected and histologically confirmed as 
an adrenocortical adenoma. We review the clinical manifestations, diagnosis, and 
management of CS associated with urolithiasis and AKI. Early recognition and 
careful monitoring of urolithiasis in CS patients are important to avoid severe 
complications of urolithiasis.
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Cushing syndrome (CS) describes clinical manifestations due to chronic exposure to excess 
glucocorticoids.1) The most common cause of CS is iatrogenic,1) and endogenous CS occurs 
rarely, with an overall incidence of 0.7 to 2.4 cases per million people per year.2) Among the 
new cases of endogenous CS, only about 10% occur in children.3,4) CS is classified into two 
types, adrenocorticotropic hormone (ACTH)-dependent and ACTH-independent CS. 
Cushing disease (CD), overproduction of ACTH by a pituitary tumor, is the most common 
cause of ACTH-dependent CS.4) ACTH-independent CS, including adrenal adenoma, adrenal 
carcinoma, and micronodular adrenal hyperplasia, accounts for approximately 15% of CS in 
childhood.3) Adrenocortical tumors are rare in children and account for approximately 0.2% of 
all pediatric neoplasm.5) Moreover, cortisol-secreting adrenal adenomas are even more rare.6)
The clinical presentation of CS varies according to extent and duration of glucocorticoid 
excess.3,4) Urolithiasis is a rare disease in children,7) but one of the common complications of 
CS.8) Although urolithiasis is more common in children with CS than in those without, it is 
usually underrecognized because of its rarity.7,9) Early recognition of urolithiasis is important 
in pediatric CS, particularly with respect to treatment outcomes. Early diagnosis of urolithiasis 
allows conservative management or stone removal without complications. In contrast, late 
diagnosis can be followed by serious complications, including urinary tract infection (UTI), 
sepsis, hematuria, and acute kidney injury (AKI).9,10)
Here, we report the first case of a patient with CS associated with AKI due to urolithiasis. 
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This 6-year-old boy was treated with etomidate for hypercor-
tisolism and continuous renal replacement therapy (CRRT) for 
renal function, followed by surgery for an adrenal adenoma and 
ureteral stones.
Case report
A 6-year-old boy was referred to our center for evaluation 
of an adrenal mass. Prior to transfer, he visited the Emergency 
Department of another hospital with the chief complaint 
of generalized tonic-clonic type seizure. He was diagnosed 
with posterior reversible encephalopathy syndrome due to 
hypertension based on brain computed tomography (CT) 
and magnetic resonance imaging (MRI). Abdominal CT for 
evaluation of secondary hypertension showed an adrenal mass 
suggestive of pheochromocytoma. The patient was treated with 
oral nifedipine (Adalat OROS, Bayer Pharmaceuticals, Newbury, 
UK), intravenous (IV) labetalol HCl (Labesin, Myungmoon 
Pharmacueticals, Seoul, Korea), and IV dexamethasone for 
hypertensive encephalopathy and transferred to our center for 
further evaluation and surgical resection of the mass.
The patient was born at 40 weeks of gestation and had no 
remarkable perinatal complications or medical and treatment 
history. Family history was significant for hyperthyroidism in 
his mother and thyroid cancer in his grandfather. He had no 
symptoms of headache, palpitation, or diaphoresis. He had 
gained 20 kg of weight in the past 10 months. The patient’ vital 
signs were as follows: pulse rate, 110 beats/min; blood pressure, 
170/110 mmHg (>99th percentile); respiratory rate, 18 times/
min; and body temperature, 36.6℃. On physical examination, 
the patient had moon face, central obesity, Buffalo hump, 
abdominal striae, and hirsutism (Fig. 1). His anthropometric 
measurements were as height; 125 cm (1.21 height standard 
deviation score [SDS]) weight; 35 kg (2.54 weight SDS), body 
mass index; 23.04 kg/m2 (>97th percentile).
On laboratory tests, complete blood counts, electrolytes, 
liver function, and renal functions tests were normal. Fasting 
glucose was 96 mg/dL (normal <100 mg/dL), and hemoglobin 
A1c level was 5.7% (normal, 4.0%–6.0%). Urine analysis 
showed proteinuria and glycosuria, and the urine calcium/
creatinine ratio was 0.23 (normal, <0.14). Electrocardiogram, 
echocardiography, and kidney doppler ultrasonography 
findings were normal.
Abdominal CT showed a 2.7-cm-sized heterogeneously 
enhanced mass lesion with a CT attenuation value of 25.1 
Hounsfield units (HU) in the right adrenal gland, suggesting 
pheochromocytoma, and a tiny stone in the right distal ureter 
(Fig. 2). Abdominal MRI showed a 3.3-cm-sized enhancing mass 
in the right adrenal gland without signal drop in the fat tissue on 
the opposed phase, also suggesting pheochromocytoma.
Endocrinologic tests suggested ACTH-independent CS due 
(A) (B)
Fig. 1. (A) General appearance of the patient 10 months before admission. (B) 
General appearance of the patient with moon face, obesity, and hirsutism at 
admission.
(A) (B)
Fig. 2. Abdominal computed tomography revealed a 2.7-cm-sized mass in the right adrenal gland (black arrows) in coronal (A) and transverse 
images (B).
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to adrenocortical tumor with the following findings: elevated 
24-hour urinary free cortisol (UFC), 1529.2 μg/day (normal, 
58.0–403.0 μg/day); elevated midnight serum cortisol level, 26.4 
μg/dL (normal, <2.0 μg/dL); and unsuppressed serum cortisol 
level after low-dose dexamethasone suppression test (DST), 
30.9 μg/dL (normal, <5.0 μg/dL). As the plasma ACTH level at 
midnight and 8:00 AM were undetectable, at less than 1.5 pg/mL 
(normal, 7.2–63.3 pg/mL), and an adrenal mass was detected 
in abdominal CT and MRI, high-dose DST was not performed. 
Primary aldosteronism and pheochromocytoma were ruled 
out with the following findings: aldosterone/renin ratio, 11 ng/
dL per ng/mL/hr (normal <20 ng/dL per ng/mL/hr); plasma 
metanephrine, 0.07 nmol/L (normal, 0–0.50 nmol/L); plasma 
normetanephrine, 0.09 nmol/L (normal, 0–0.09 nmol/L); 24-
hour urine metanephrine, 65.9 μg/day (normal, 52–341 μg/
day); and 24-hour urine normetanephrine, 86.9 μg/day (normal, 
88.0–444.0 μg/day).
While waiting for surgery, the patient complained of 
abdominal pain, hematuria, and anuria. Abdominal CT was 
performed again and showed bilateral distal ureter stones 
without changes in the adrenal mass (Fig. 3). The patient started 
getting drowsy, and his blood pressure was not well-controlled 
despite the maximum doses of oral losartan K (Cozaar, MSD-
Korea, Seoul, Korea), spironolactone (Aldactone, Pfizer AG, 
Zrich, Schweiz), minoxidil (Minoxidil, Hyundai PharmCo. Ltd., 
Seoul, Korea), and I V nicardipine (Perdipine, Dong-A Pharm., 
Seoul, Korea). Blood urea nitrogen and creatinine levels were 
elevated to 41.5 mg/dL (normal, 8.0–18.5 mg/dL) and 2.32 
mg/dL (normal, 0.32–0.70 mg/dL), respectively. Because his 
condition deteriorated rapidly with AKI, he was transferred 
to the intensive care unit (ICU) and underwent CRRT before 
preparation of ureteral stent indwelling. As fever developed and 
his C-reactive protein level was elevated to 135.1 mg/L (normal, 
0–8.0 mg/L), broad-spectrum antibiotics were administered. To 
control hypercortisolism, we started IV etomidate infusion at 
a rate of 0.03 mg/kg/hr. Serum cortisol level was assessed every 
4–6 hours, and the dose of etomidate was decreased to 0.02 mg/
kg/hr to normalize the serum cortisol level. When the serum 
cortisol level reached 5.5 μg/dL (normal, 6.0–18.4 μg/dL), IV 
hydrocortisone infusion at a rate of 15 mg/m2/24 hr was started 
and used to maintain the serum cortisol level between 8.7 μg/
dL and 12.4 μg/dL. After maintaining a normal cortisol level 
and performing ureteral stent indwelling, the patient’s blood 
pressure improved, and losartan K, minoxidil, and nicardipine 
were discontinued. After confirming improvement of oliguria 
and renal function, CRRT was discontinued. In preparation 
for resection of the adrenal mass, IV etomidate infusion was 
discontinued 1 hour before the surgery, and IV hydrocortisone 
was increased to 100 mg/m2/24 hr. The patient underwent 
laparotomy and resection of a well-encapsulated right adrenal 
mass, which was histologically confirmed as an adrenocortical 
adenoma. The surgery was successfully performed without 
perioperative complications. Postoperatively, his condition was 
significantly improved, and IV hydrocortisone was changed to 
oral medication. The ureteral stones were removed, and analysis 
showed calcium carbonate apatite. The patient was discharged 
with replacement therapy of hydrocortisone at 15 mg/m2/day.
Discussion
Our patient showed seizure due to hypertensive encephalo-
pathy and AKI due to bilateral ureteral stones, as well as 
common features of CS such as rapid weight gain, moon face, 
central obesity, Buffalo hump, and purple striae. Although a case 
of hypertensive encephalopathy associated with CS has been 
reported,11) to our knowledge, there is no reported case of CS 
with AKI due to urolithiasis.
Urolithiasis is a rare disease in children, with an annual 
incidence of 36 to 57 per 100,000 children in the United 
States.9) Urolithiasis in children is more common in those 
with risk factors such as urinary tract anomaly or infection, 
neurogenic bladder, tubular disorder, genetic disorder, or 
systemic disease.7) In these patients, excessive solutes including 
calcium, oxalate, phosphate, citrate, uric acid, and cysteine in 
the urine and their crystallization promote stone formation.9) 
Rahman et al.8) reported that kidney stones were more 
common in children with CD than in those without. Obesity, 
insulin resistance, hypertension, and dyslipidemia, as well as 
hypercalciuria, hyperuricosuria, and hypercystinuria induced 
by hypercortisolism increase the risk of urolithiasis in CS.8) 
Our patient showed obesity, hypertension, dyslipidemia, and 
hypercalciuria. In patients with these risk factors, careful 
monitoring for urolithiasis is required. The calcium carbonate 
apatite found in our patient's stone analysis is associated 
with UTI. Carbon dioxide, formed by breakdown of urea by 
urease produced by bacteria, breaks down to carbonate, which 
combines with calcium and phosphate to form a calcium 
carbonate apatite stone. This stone is usually asymptomatic or 
manifests as fever, flank, or abdominal pain, hematuria, UTI, 
sepsis, and/or renal insufficiency. The standard diagnostic 
modality for such stones is CT, and broad-spectrum antibiotics Fig. 3. Abdominal computed tomography revealed bilateral distal ureter stones 
(black arrows).
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with emergency decompression are required for improving 
obstructive pyelonephritis. Although older studies have 
proposed withholding emergency decompression in patients 
with pyelonephritis,12) prompt decompression via ureteral 
stent insertion or nephrostomy tube now is preferred for 
better prognosis.13) Although a unilateral ureteral stone 
was observed on initial abdominal CT, our patient had no 
symptoms indicating urolithiasis. However, fever, abdominal 
pain, hematuria, and anuria occurred later due to bilateral 
ureteral obstruction. In patients with CS accompanied by these 
symptoms, proper evaluation of urolithiasis is required.
In this case, AKI occurred due to bilateral ureteral obstruc-
tions by stones. The etiology of AKI is classified into prerenal, 
intrinsic renal, and postrenal, with intrinsic renal cause being 
the most frequent (63.8%), followed by postrenal (24.1%.) 
and prerenal cause (9.5%). Among postrenal causes of AKI, 
obstructive urolithiasis is the most common (85.7%).14) 
Although AKI is associated with longer ICU stay and 
mechanical ventilation, higher mortality rates, and chronic 
kidney disease (CKD), no single treatment modality has been 
shown to reverse AKI, and renal replacement therapy often is 
required.15) Consequently, careful monitoring and management 
of AKI etiologies are required for hospitalized children. In 
patients with CS, although CKD with a decreased glomerular 
filtration rate is caused by chronic glucocorticoid exposure,16) 
there are no studies on the relationship between CS and AKI.
In investigation of a patient with suspected CS, step-by-step 
biochemical laboratory tests are required. Loss of circadian 
rhythm of plasma cortisol, elevated midnight salivary cortisol, 
increased UFC excretion, and unsuppressed cortisol response 
after overnight/low-dose DST are positive findings for CS 
diagnosis. After confirming CS, subsequent evaluations 
including midnight ACTH, high-dose DST, corticotropin-
releasing factor test, and inferior petrosal sinus sampling should 
be performed to determine the cause of CS, if indicated. Imaging 
studies including CT/MRI scanning of pituitary and adrenals 
and scintigraphy studies are required for CS localization.1,3,4) 
Although the radiological findings on abdominal CT and 
MRI suggested pheochromocytoma, our case was diagnosed 
as CS by clinical manifestations, biochemical studies including 
elevated UFC, and unsuppressed cortisol level after low-dose 
DST; whereas a normal range of catecholamine was noted in 
urine and serum. Furthermore, adrenocortical adenoma was 
confirmed upon pathological examination. In general, adrenal 
adenomas contain abundant intracellular lipids, which can 
easily be distinguished from pheochromocytoma through 
CT or MRI. As intracellular lipids of the adrenal adenoma 
reduce CT attenuation, attenuation of lipid-rich adenoma is 
less than 10 HU.17) However, lipid-poor adenoma is difficult 
to distinguish from pheochromocytoma through CT or MRI 
because of insufficient intracellular lipids.17,18) Due to overlap 
of clinical manifestations between adrenal adenoma and 
pheochromocytoma, the possibility of lipid-poor adrenal 
adenoma should be considered in cases with both imaging 
findings of pheochromocytoma and clinical manifestations of 
CS.
In our patient, IV etomidate was administered to control 
hypercortisolism as resection of the adrenal mass was delayed 
due to deteriorating condition. Etomidate, a carboxylated 
imidazole, blocks cortisol production by inhibiting the 
activity of  the adrenal enzyme 11β-hydroxylase, which 
converts deoxycortisol into cortisol and can be used for severe 
hypercortisolism before CS surgery to control complications of 
hypercortisolism.19) Although there is little pediatric experience 
with etomidate, Greening et al.20) reported a case of pediatric 
CD treated with IV etomidate at a rate of 0.03 mg/kg/hr prior to 
surgical cure.
Herein, we report the first case of CS with AKI caused by 
urolithiasis. Variable risk factors were associated with bilateral 
ureteral stones in our patient and caused deteriorated condition 
and AKI. This case demonstrates that patients with CS require 
attentive evaluation and proper management of urolithiasis as 
one of the clinical manifestations of CS.
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